Express News | HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $50 Price Target
Biomea Fusion Is Maintained at Neutral by JP Morgan
Biomea Fusion Is Maintained at Neutral by JP Morgan
Express News | JP Morgan Maintains Neutral on Biomea Fusion, Raises Price Target to $15
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Repligen (RGEN) and Agenus (AGEN)
Barclays Sticks to Its Buy Rating for Biomea Fusion (BMEA)
Biomea Fusion GAAP EPS of -$1.09 Misses by $0.02
Express News | Biomea Fusion Inc : JP Morgan Raises Target Price to $15 From $14
Express News | Biomea Fusion Q1 EPS $(1.09) Misses $(0.91) Estimate
Biomea Fusion 1Q Loss/Shr $1.09 >BMEA
Biomea Fusion 1Q Loss/Shr $1.09 >BMEA
Express News | Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
Press Release: Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights -- Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes
DJT, BGFV and REAL Are Among After Hour Movers
Biomea Fusion Is Maintained at Outperform by Oppenheimer
Biomea Fusion Is Maintained at Outperform by Oppenheimer
Express News | Oppenheimer Maintains Outperform on Biomea Fusion, Maintains $70 Price Target
Biomea Fusion Drops as JPMorgan Downgrades on Data for Lead Asset
Express News | Biomea Fusion Shares Are Trading Lower After JP Morgan Downgraded the Stock From Overweight to Neutral and Lowered Its Price Target From $51 to $14
Biomea Fusion Cut to Neutral From Overweight by JP Morgan
Biomea Fusion Cut to Neutral From Overweight by JP Morgan
Express News | JP Morgan Downgrades Biomea Fusion to Neutral, Lowers Price Target to $14
Biomea Fusion Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/02/2024 3.74% JP Morgan $51 → $14 Downgrades Overweight → Neutral 04/01/2024 270.51% HC Wainwright & Co
Biomea Fusion (BMEA) Receives a Buy From Scotiabank